Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
05/16/2025 | CALL | $2.50 | 141 | +71 | +101.43% |
05/16/2025 | PUT | $0.50 | 20 | +20 | |
04/17/2025 | CALL | $1.00 | 244 | +16 | +7.02% |
06/20/2025 | CALL | $2.50 | 1,226 | +14 | +1.16% |
09/19/2025 | CALL | $2.50 | 996 | +10 | +1.01% |
09/19/2025 | CALL | $1.00 | 87 | +2 | +2.35% |
09/19/2025 | PUT | $1.00 | 0 | 0 | |
09/19/2025 | PUT | $1.50 | 14 | 0 | |
09/19/2025 | PUT | $2.00 | 0 | 0 | |
09/19/2025 | PUT | $2.50 | 10 | 0 | |
09/19/2025 | PUT | $5.00 | 3 | 0 | |
09/19/2025 | PUT | $7.50 | 0 | 0 |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Fidelity Growth Company Fund | 4.35% | 4.76M | 5.99M |
Fidelity Series Growth Company Fund | 1.52% | 1.66M | 2.1M |
Vanguard Total Stock Market Index Fund | 1.48% | 1.62M | 2.04M |
iShares Russell 2000 ETF | 1.02% | 1.11M | 1.4M |
Fidelity Growth Company K6 Fund | 0.82% | 892.97k | 1.13M |
Vanguard Extended Market Index Fund | 0.68% | 747.48k | 941.82k |
iShares Russell 2000 Value ETF | 0.47% | 512.72k | 646.02k |
Fidelity Small Cap Index Fund | 0.40% | 440.43k | 554.94k |
iShares NASDAQ Biotechnology ETF | 0.27% | 289.73k | 365.06k |
Price (T.Rowe) Health Sciences Fund | 0.26% | 288.95k | 364.08k |
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
03/20 08:01 am
GlobeNewswire Inc.
Read moreInvivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
11/06 09:01 am
GlobeNewswire Inc.
Read moreInvivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
11/06 08:01 am
GlobeNewswire Inc.
Read moreInvivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
10/16 07:01 am
GlobeNewswire Inc.
Read moreInvivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
07/01 07:01 am
GlobeNewswire Inc.
Read moreInvivyd to Participate at the Jefferies Global Healthcare Conference
06/03 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
05/31 07:00 am
GlobeNewswire Inc.
Read moreInvivyd Elects Two New Independent Members to its Board of Directors
05/22 07:00 am
GlobeNewswire Inc.
Read moreInvivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
05/13 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
05/09 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
05/07 07:30 am
GlobeNewswire Inc.
Read moreInvivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
05/02 05:13 pm
GlobeNewswire Inc.
Read moreInvivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
04/30 07:30 am
GlobeNewswire Inc.
Read moreInvivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
04/15 07:30 am
GlobeNewswire Inc.
Read moreInvivyd Announces CEO Transition
04/12 07:30 am
GlobeNewswire Inc.
Read moreKura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
04/05 08:01 am
Benzinga
Read moreInvivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
04/04 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
03/28 07:00 am
GlobeNewswire Inc.
Read moreTesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
03/26 10:36 am
Benzinga
Read moreAehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
03/25 10:32 am
Benzinga
Read moreInvivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
03/22 03:28 pm
GlobeNewswire Inc.
Read moreInvivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
02/05 05:02 pm
GlobeNewswire Inc.
Read moreApple To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday
01/18 08:50 am
Benzinga
Read moreAll You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
01/12 01:00 pm
Zacks Investment Research
Read moreInvivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
12/23 06:29 am
The Motley Fool
Read moreInvivyd (IVVD) Surges on Positive Data From COVID-19 Study
12/19 12:52 pm
Zacks Investment Research
Read moreBluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
12/19 11:19 am
Benzinga
Read moreCrude Oil Rises 3%; US Housing Market Index Increases In December
12/18 01:17 pm
Benzinga
Read moreInvivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
12/18 08:00 am
GlobeNewswire Inc.
Read moreInvivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
11/02 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd to Participate in Upcoming Investor Conferences
10/31 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
09/11 07:00 am
GlobeNewswire Inc.
Read moreInvivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
08/29 01:13 pm
Zacks Investment Research
Read moreInvivyd Reports Second Quarter 2023 Financial Results and Business Highlights
08/10 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
08/03 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd Announces Appointment of Sara Cotter to Board Of Directors
07/27 04:01 pm
GlobeNewswire Inc.
Read moreInvivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
06/26 07:00 am
GlobeNewswire Inc.
Read moreInvivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
06/22 07:00 am
GlobeNewswire Inc.
Read moreInvivyd to Participate at the Jefferies Healthcare Conference
06/01 07:00 am
GlobeNewswire Inc.
Read more